SPDR S&P Pharmaceuticals ETF (XPH)
- Previous Close
40.57 - Open
40.27 - Bid 40.22 x 1300
- Ask 40.24 x 1200
- Day's Range
39.94 - 40.28 - 52 Week Range
34.67 - 45.62 - Volume
6,773 - Avg. Volume
31,650 - Net Assets 194.12M
- NAV 40.59
- PE Ratio (TTM) 14.50
- Yield 1.46%
- YTD Daily Total Return -2.12%
- Beta (5Y Monthly) 0.70
- Expense Ratio (net) 0.35%
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
SPDR State Street Global Advisors
Fund Family
Health
Fund Category
194.12M
Net Assets
2006-06-19
Inception Date
Performance Overview: XPH
Trailing returns as of 6/7/2024. Category is Health.
People Also Watch
Holdings: XPH
Top 10 Holdings (49.20% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: XPH
ASML: Raising Our Fair Value Estimate to EUR 900; TSMC Adopting High-NA EUV Earlier Than Expected
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 05/24/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Lowering target price to $58.00
RAMBUS INC has an Investment Rating of HOLD; a target price of $58.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about VNO?
VORNADO REALTY TRUST has an Investment Rating of SELL; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target